Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2025-08-05 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Grant of U.S. Patent for OptiMAL
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details the grant of a U.S. patent for the company's OptiMAL platform. Since this is a general corporate announcement regarding operational/intellectual property developments that does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the 'Regulatory Filings' (RNS) category.
2025-08-05 English
Issue Notification: US Patent Update
Legal Proceedings Report Classification · 99% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate update regarding a US Patent Issue Notification for Fusion Antibodies plc. Since this is a general corporate announcement regarding operational/intellectual property news that does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the fallback category for regulatory announcements.
2025-07-24 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement filed with RNS (RNS Number : 6335Q) dated July 11, 2025. The core subject is a 'Director/PDMR Shareholding' notification concerning Colin Walsh, a Non-Executive Director. It details the transfer of ordinary shares and the resulting change in his beneficial interest. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing' (DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2025-07-11 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number : 8917K' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces the 'Total Voting Rights' of the company as of June 2, 2025, which is a standard regulatory disclosure required by exchanges like AIM/LSE. This type of general, mandatory regulatory announcement that doesn't fit a more specific category (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2025-06-02 English
Update on U.S. Patent for OptiMAL®
Regulatory Filings Classification · 100% confidence The document is a regulatory news announcement (RNS) issued by Fusion Antibodies PLC regarding a notice of allowance for a U.S. patent application. It does not fit into specific categories like financial reports, dividends, or management changes. As it is a general corporate update disseminated via the London Stock Exchange's RNS service, it falls under the 'Regulatory Filings' category.
2025-05-22 English
Investor presentation
Investor Presentation Classification · 95% confidence The document is an announcement from Fusion Antibodies plc regarding an upcoming investor presentation. It provides details on the date, time, and platform (Investor Meet Company) for the event, which is intended to accompany a recent trading update. It explicitly states it is a 'Reach - Non-regulatory announcement' and does not contain the actual presentation slides or financial report itself, but rather serves as a notification of an event. Therefore, it falls under the category of a general regulatory/corporate announcement.
2025-05-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.